There is no way PFE is going to pay PSDV $168 MIL over 3 years to bring Latanoprost to market, then give them 20% of the profits going forward. Additionally, on a company with a MARKET CAP of what will soon be 400 MIllion!. Think about it. They will enjoy the revenue from Illuvien ( the best, MOST AFFORDABLE drug to treat DME) then sail through the phase III trial of Latanoprost to treat glaucoma. I keep hearing that Avastin and Lucentis are potential competitors. That only means that the ROACH machine is the other interested party. Lucentis is too $$ and Avastin has some "DELIVERY ISSUES" but is "WAY" affordable. The feds want something affordable. Shorts are going to eat it big, but there are only 250K. Good luck to longs.